Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 51

Sort by

Sort Order Select

Journal Articles

Initial Results from Summit: An Ongoing, 3-Part, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Study of Bezuclastinib in Adult Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM)

Prithviraj Bose, Stephen T. Oh, Brian Modena, Anthony M. Hunter, Cem Akin, Mariana Castells, Michael Manning, Richard Herrscher, Frank Siebenhaar, Daniel J. DeAngelo, Tracy I. George, Benjamin Exter, Jenna Zhang, Amanda Pilla, Hina Jolin, Rachael Easton, Lindsay A.M Rein

Blood (2023) 142 (Supplement 1): 77.

https://doi.org/10.1182/blood-2023-178927

Published: 2023

Journal Articles

Elenestinib, an Investigational, Next Generation KIT D816V Inhibitor, Reduces Mast Cell Burden, Improves Symptoms, and Has a Favorable Safety Profile in Patients with Indolent Systemic Mastocytosis: Analysis of the Harbor Trial

Blood (2023) 142 (Supplement 1): 76.

https://doi.org/10.1182/blood-2023-188904

Published: 2023

Journal Articles

Deep and Durable Cytogenetic and Molecular Responses with Pemigatinib in Myeloid/Lymphoid Neoplasms with Fibroblast Growth Factor Receptor 1 Rearrangement: The Fight-203 Study

Blood (2023) 142 (Supplement 1): 4551.

https://doi.org/10.1182/blood-2023-180945

Published: 2023

Journal Articles

Safety and Efficacy of Bezuclastinib (CGT9486), a Novel, Highly Selective, Potent KIT D816V Tyrosine Kinase Inhibitor, in Patients with Advanced Systemic Mastocytosis (AdvSM): Results from Part 1 of the Phase 2 Apex Trial

Pankit Vachhani, Tsewang Tashi, Gary J. Schiller, Stephanie Lee, Miguel Piris Villaespesa, Helena Pomares, Cristina Bulai Livideanu, Jonathan Lambert, Anthony M. Hunter, Tracy I. George, Cristina Papayannidis, Khalid Shoumariyeh, Rita Petroro, Jenna Zhang, Amanda Pilla, Hina Jolin, Rachael Easton, Vinod Pullarkat

Blood (2023) 142 (Supplement 1): 4567.

https://doi.org/10.1182/blood-2023-178885

Published: 2023

Journal Articles

Preliminary Safety and Efficacy from Apex, a Phase 2 Study of Bezuclastinib (CGT9486), a Novel, Highly Selective, Potent KIT D816V Tyrosine Kinase Inhibitor, in Adults with Advanced Systemic Mastocytosis (AdvSM)

Daniel J. DeAngelo, Vinod A. Pullarkat, Miguel Piris-Villaespesa, Tracy I. George, Jay L. Patel, Celalettin Ustun, Prithviraj Bose, Mark L Heaney, Jessica Sachs, Lei Sun, Amanda Pilla, Benjamin Exter, Hina A. Jolin, Tsewang Tashi

Blood (2022) 140 (Supplement 1): 1512–1513.

https://doi.org/10.1182/blood-2022-156311

Published: 2022

Journal Articles

Summit: A 3-Part, Phase 2 Study of Bezuclastinib (CGT9486), an Oral, Selective, and Potent KIT D816V Inhibitor, in Adult Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM)

Cem Akin, Frank Siebenhaar, Michael W. Deininger, Daniel J. DeAngelo, Tracy I. George, Mariana Castells, Matthew Giannetti, Jason Gotlib, Jessica Sachs, Amanda Pilla, Hina A. Jolin, Prithviraj Bose

Blood (2022) 140 (Supplement 1): 6838–6839.

https://doi.org/10.1182/blood-2022-156326

Published: 2022

Journal Articles

Subclonal KIT D816V Mutations Are Prevalent in Chronic Myelomonocytic Leukemia and Correlate with Distinct Phenotypic Features

Blood (2022) 140 (Supplement 1): 9824–9827.

https://doi.org/10.1182/blood-2022-164816

Published: 2022

Journal Articles

Clonal Dynamics of ASM-AHN with Avapritinib Treatment

Xiaomeng Huang, Jonathan M. Ahmann, Opal S. Chen, Yi Qiao, Anthony D. Pomicter, Gabor T. Marth, Tracy I. George, Michael W. Deininger

Blood (2022) 140 (Supplement 1): 6737–6738.

https://doi.org/10.1182/blood-2022-167701

Published: 2022

Journal Articles

FIGHT-203, an Ongoing Phase 2 Study of Pemigatinib in Patients With Myeloid/Lymphoid Neoplasms (MLNs) With Fibroblast Growth Factor Receptor 1 ( FGFR1 ) Rearrangement (MLN FGFR1 ): A Focus on Centrally Reviewed Clinical and Cytogenetic Responses in Previously Treated Patients

Srdan Verstovsek, Jason Gotlib, Alessandro M. Vannucchi, Alessandro Rambaldi, Andreas Reiter, William Shomali, Tracy I. George, Jay L. Patel, Philomena Colucci, Huiling Zhen, Natalia Oliveira, Jean-Jacques Kiladjian

Blood (2022) 140 (Supplement 1): 3980–3982.

https://doi.org/10.1182/blood-2022-163099

Published: 2022

Journal Articles

Avapritinib As First-Line Therapy in Patients with Advanced Systemic Mastocytosis: Efficacy and Safety from the Pathfinder Clinical Study

Deepti H. Radia, Jason Gotlib, Mark W. Drummond, Tracy I. George, Hui-Min Lin, Saša Dimitrijević, Javier I. Munoz-Gonzalez, Ilda Bidollari, Michael W. Deininger, Daniel J. DeAngelo, Andreas Reiter

Blood (2022) 140 (Supplement 1): 1509–1511.

https://doi.org/10.1182/blood-2022-166986

Published: 2022

Journal Articles

AZURE: A Phase 1/2 Study of Blu-263 As Monotherapy and in Combination with Azacitidine in Patients with Advanced Systemic Mastocytosis

Daniel J. DeAngelo, Andreas Reiter, Tracy I. George, Deepti H. Radia, Marissa Devlin, Saša Dimitrijević, Mikael Rinne, Robyn Scherber, Jason Gotlib

Blood (2022) 140 (Supplement 1): 6877–6878.

https://doi.org/10.1182/blood-2022-167410

Published: 2022

Journal Articles

An Updated Analysis on Safety and Efficacy of Avapritinib in Patients with Advanced Systemic Mastocytosis from the Explorer Clinical Study: Long-Term Efficacy and Safety

Daniel J. DeAngelo, Deepti H. Radia, Tracy I. George, William A. Robinson, Albert T. Quiery, Mark W. Drummond, Prithviraj Bose, Elizabeth O. Hexner, Elliott Winton, Hans-Peter Horny, Meera Tugnait, Hui-Min Lin, Saša Dimitrijević, Javier I. Munoz-Gonzalez, Ilda Bidollari, Michael W. Deininger, Jason Gotlib

Blood (2022) 140 (Supplement 1): 3932–3934.

https://doi.org/10.1182/blood-2022-167593

Published: 2022

Journal Articles

A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with Myelofibrosis Refractory or Intolerant to JAK Inhibitors

Srinivas K. Tantravahi, Soo Jin Kim, Divya Sundar, Ami B. Patel, Anthony D. Pomicter, Kenneth M. Boucher, Kamal Chamoun, Jatin Shah, Anton Rets, Tracy I. George, Josef T. Prchal, Michael W. Deininger

Blood (2021) 138 (Supplement 1): 143.

https://doi.org/10.1182/blood-2021-153940

Published: 2021

Journal Articles

Effective Control of Advance Systemic Mastocytosis with Avapritinib: Mutational Analysis from the Explorer Clinical Study

Michael W. Deininger, Daniel J. DeAngelo, Deepti H. Radia, Tracy I. George, Guang Yang, Jayita Sen, Hui-Min Lin, Brenton Mar, Jason Gotlib

Blood (2021) 138 (Supplement 1): 318.

https://doi.org/10.1182/blood-2021-150872

Published: 2021

Journal Articles

A Phase 2 Study of Pemigatinib (FIGHT-203; INCB054828) in Patients with Myeloid/Lymphoid Neoplasms (MLNs) with Fibroblast Growth Factor Receptor 1 (FGFR1) Rearrangement (MLN FGFR1 )

Jason Gotlib, Jean-Jacques Kiladjian, Alessandro Vannucchi, Alessandro Rambaldi, Andreas Reiter, William Shomali, Tracy I. George, Jay L. Patel, Philomena Colucci, Chris Walker, Huiling Zhen, Srdan Verstovsek

Blood (2021) 138 (Supplement 1): 385.

https://doi.org/10.1182/blood-2021-148103

Published: 2021

Journal Articles

Efficacy of Avapritinib in Patients with Advanced Systemic Mastocytosis: Hematologic and Bone Marrow Responses from the Phase 2 Open-Label, Single-Arm, Pathfinder Study

Tracy I. George, Kristin H. Karner, Karen A. Moser, Anton Rets, Michelle Fredericks, Andreas Reiter, Deepti H. Radia, Michael W. Deininger, Hui-Min Lin, Jayita Sen, Jason Gotlib, Saša Dimitrijević, Daniel J. DeAngelo

Blood (2021) 138 (Supplement 1): 2565.

https://doi.org/10.1182/blood-2021-146873

Published: 2021

Journal Articles

In Depth Analysis of Blastic Plasmacytoid Dendritic Cell Neoplasm Based on a Comprehensive Literature Database of Cases

Robert S. Ohgami, Phyu Aung, Alejandro Ariel Gru, Mohammad O Hussaini, Christiane Querfeld, Kelou Yao, Corinn Small, Sumanth Gollapudi, David L Jaye, Sa A Wang, Sheeja T Pullarkat, Tracy I. George

Blood (2021) 138 (Supplement 1): 4383.

https://doi.org/10.1182/blood-2021-151694

Published: 2021

Journal Articles

A Phase 2 Study of Bezuclastinib (CGT9486), an Oral, Selective, and Potent KIT D816V Inhibitor, in Adult Patients with Advanced Systemic Mastocytosis (AdvSM)

Jason Gotlib, Tracy I. George, Michael W. Deininger, Tsewang Tashi, Vinod A. Pullarkat, Prithviraj Bose, Francis Payumo, Amanda Pilla, Hina Jolin, Jessica Sachs, Daniel J. DeAngelo

Blood (2021) 138 (Supplement 1): 3636.

https://doi.org/10.1182/blood-2021-145928

Published: 2021

Journal Articles

A 3-Part, Phase 2 Study of Bezuclastinib (CGT9486), an Oral, Selective, and Potent KIT D816V Inhibitor, in Adult Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM)

Frank Siebenhaar, Jason Gotlib, Michael W. Deininger, Daniel J. DeAngelo, Francis Payumo, George Mensing, Hina Jolin, Jessica Sachs, Tracy I. George

Blood (2021) 138 (Supplement 1): 3642.

https://doi.org/10.1182/blood-2021-147072

Published: 2021

Journal Articles

Treatment Patterns and Outcomes of Patients with Lower-Risk Myelodysplastic Syndromes in the Connect ® Myeloid Disease Registry

Rami S. Komrokji, Tracy I. George, Harry P. Erba, Bart L. Scott, David L. Grinblatt, Jaroslaw P. Maciejewski, Gail J. Roboz, Michael R. Savona, Guillermo Garcia-Manero, Irene S. DeGutis, Pavel Kiselev, Edward Yu, Adeola Y. Makinde, Mikkael A. Sekeres

Blood (2021) 138 (Supplement 1): 3686.

https://doi.org/10.1182/blood-2021-145853

Published: 2021

NARROW

Initial Results from Summit: An Ongoing, 3-Part, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Study of Bezuclastinib in Adult Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM)

Elenestinib, an Investigational, Next Generation KIT D816V Inhibitor, Reduces Mast Cell Burden, Improves Symptoms, and Has a Favorable Safety Profile in Patients with Indolent Systemic Mastocytosis: Analysis of the Harbor Trial

Deep and Durable Cytogenetic and Molecular Responses with Pemigatinib in Myeloid/Lymphoid Neoplasms with Fibroblast Growth Factor Receptor 1 Rearrangement: The Fight-203 Study

Safety and Efficacy of Bezuclastinib (CGT9486), a Novel, Highly Selective, Potent KIT D816V Tyrosine Kinase Inhibitor, in Patients with Advanced Systemic Mastocytosis (AdvSM): Results from Part 1 of the Phase 2 Apex Trial

Preliminary Safety and Efficacy from Apex, a Phase 2 Study of Bezuclastinib (CGT9486), a Novel, Highly Selective, Potent KIT D816V Tyrosine Kinase Inhibitor, in Adults with Advanced Systemic Mastocytosis (AdvSM)

Summit: A 3-Part, Phase 2 Study of Bezuclastinib (CGT9486), an Oral, Selective, and Potent KIT D816V Inhibitor, in Adult Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM)

Subclonal KIT D816V Mutations Are Prevalent in Chronic Myelomonocytic Leukemia and Correlate with Distinct Phenotypic Features

Clonal Dynamics of ASM-AHN with Avapritinib Treatment

FIGHT-203, an Ongoing Phase 2 Study of Pemigatinib in Patients With Myeloid/Lymphoid Neoplasms (MLNs) With Fibroblast Growth Factor Receptor 1 ( FGFR1 ) Rearrangement (MLN FGFR1 ): A Focus on Centrally Reviewed Clinical and Cytogenetic Responses in Previously Treated Patients

Avapritinib As First-Line Therapy in Patients with Advanced Systemic Mastocytosis: Efficacy and Safety from the Pathfinder Clinical Study

AZURE: A Phase 1/2 Study of Blu-263 As Monotherapy and in Combination with Azacitidine in Patients with Advanced Systemic Mastocytosis

An Updated Analysis on Safety and Efficacy of Avapritinib in Patients with Advanced Systemic Mastocytosis from the Explorer Clinical Study: Long-Term Efficacy and Safety

A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with Myelofibrosis Refractory or Intolerant to JAK Inhibitors

Effective Control of Advance Systemic Mastocytosis with Avapritinib: Mutational Analysis from the Explorer Clinical Study

A Phase 2 Study of Pemigatinib (FIGHT-203; INCB054828) in Patients with Myeloid/Lymphoid Neoplasms (MLNs) with Fibroblast Growth Factor Receptor 1 (FGFR1) Rearrangement (MLN FGFR1 )

Efficacy of Avapritinib in Patients with Advanced Systemic Mastocytosis: Hematologic and Bone Marrow Responses from the Phase 2 Open-Label, Single-Arm, Pathfinder Study

In Depth Analysis of Blastic Plasmacytoid Dendritic Cell Neoplasm Based on a Comprehensive Literature Database of Cases

A Phase 2 Study of Bezuclastinib (CGT9486), an Oral, Selective, and Potent KIT D816V Inhibitor, in Adult Patients with Advanced Systemic Mastocytosis (AdvSM)

A 3-Part, Phase 2 Study of Bezuclastinib (CGT9486), an Oral, Selective, and Potent KIT D816V Inhibitor, in Adult Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM)

Treatment Patterns and Outcomes of Patients with Lower-Risk Myelodysplastic Syndromes in the Connect ® Myeloid Disease Registry

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only